PHARMACEUTICAL COMPANIES’ STUBBORNNESS OR IDIOCY

UPDATE ON THE ROAD TO THE CURE

A REAL-TIME SCIENCE REPORT

PHARMACEUTICAL COMPANIES’ STUBBORNNESS OR IDIOCY

Ram S Bhatt, PhD

ALZHEIMER’S, DEMENTIA and PARKINSON’S diseases are growing epidemics with no cure the horizon for nearly 20 million patients worldwide. During the last thirty years, drug development for Central Nervous System (CNS) diseases has experienced tremendous setbacks worldwide as several clinical trials targeting Aß, tau, and α-synuclein failed one after another.  As much as these results have been very disappointing, they are really not surprising in view of what is published since the 1980s about the monoclonal antibody drugs derived from mouse (mouse mAbs) that were used in the failed clinical trials.

            “Today, there is not a single biologic that is FDA approved for a disease of the central nervous system where the drug traverses the blood-brain-barrier following intravenous or subcutaneous administration.          It is difficult to conclude, on the basis of a failed clinical trial, that a given biologic is not often effective for a given central nervous system disease when the biologic was never delivered to the target site in the brain.”

 William Pardridge, Bio Drugs, 31, 503 (2017)

            In spite of the overwhelming proof that mouse monoclonal antibodies do not cross the blood-brain barrier (BBB) and reach the brain, most of the big pharmaceuticals have been pouring billions of dollars into developing a cure for CNS diseases without any good outcome of the massive efforts worldwide. Who is responsible for such a colossal failure year after year and wasting stakeholders’ billions of dollars? While argument can be made that most CEOs have no science background and thus not responsible for the recurring failures, responsibility also falls upon them for not using common sense that they cannot expect better outcome for using the same old mouse mAb drugs that have been failing for CNS disease since the 1980s. The majority of the responsibility falls upon the scientific leaders, R&D Directors, Vice Presidents, and/or Chief Scientific Officers (middle management) who continue to endorse the use of failed mouse mAbs technology for CNS diseases hoping for a better outcome next time but failing again and again. The middle R&D managers of these big pharma have been the barriers to successful development of CNS disease therapies by clinging to their comfort zone ( mAbs), perhaps also job security, and not welcoming /considering new technology that may be revolutionary for overcoming problems of the BBB impermeability.

            GOOD NEWS The San Diego Biotech Company, ICB International, Inc., (“ICBII”), has developed technology to overcome the hurdles of the blood-brain brain. The technology has been demonstrated in animals to halt and reverse the disease progression. The Company is now seeking funds for human clinical trials. The company is committed to bringing its Alzheimer’s and Parkinson’s drugs to the market with or without pharma involvement

            WOULDN’T YOU LIKE TO HELP get ICBII’s drugs to market faster? The joy of being a part of this historic event can be had by helping ICBI find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the - until now - impossible. Please contact Jo Rosen at 760-773-5628 or jorosen@Parkinsonsresource.org or by contacting ICBI directly through their website http://icbii.com/ or by phone 858-455-9880.

            IMAGINE the world without Parkinson’s, MSA, or Alzheimer’s disease. JUST IMAGINE.